Table 1 Baseline characteristics
From: PPI efficacy in the reduction of variceal bleeding incidence and mortality, a meta-analysis
Author | Country | Study design | Age mean (SD) | Sex, male to female | Total number | ||
|---|---|---|---|---|---|---|---|
PPI | Placebo | PPI | Placebo | ||||
Wu 2017 [15] | Taiwan | Prospective cohort | 58.84 (16.97) | 58.94 (16.57) | 335: 146 | 106: 20 | 637 |
Ghoz 2020 [16] | USA | Retrospective cohort | 62 (11.7) | 57.7 (11.17) | 53:37 | 49: 25 | 164 |
Kim 2015 [17] | Korea | Retrospective cohort | 57.3 (10.7) | 58.8 (11.5) | 178: 41 | 100: 22 | 341 |
Hidaka 2012 [18] | Japan | RCT | 64.7 (11.5) | 61.5 (9.9) | 10: 11 | 12: 10 | 43 |
Lau 2000 [19] | China | RCT | 64 (17.2) | 67 (15.9) | 80: 40 | 80: 40 | 240 |
Lin 1997 [20] | Taiwan | RCT | 57.75 (14.9) | 63 (11.8) | 46: 4 | 43: 7 | 100 |
Kang 2016 [21] | Korea | Retrospective cohort | 53.6 (10.63) | 55.2 (9.13) | 375: 116 | 13: 1 | 505 |
Total=2030 | |||||||